Clinical trial
An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency
NCT04038502 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency
- Lead sponsor
- VA Office of Research and Development
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 1, 2019
- Completion date
- August 31, 2027
- Enrollment
- 100 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
bard1, brca1, brca2, brip1, chek1, fancl, palb2, metastatic castrate resistant prostate cancer, rad51b, rad51c, rad51d, or rad54l mutations